BioSpace News Archive

Foundation Medicine, Inc., announced that it has expanded its partnership with Sequanta Technologies Co., Ltd. to provide genomic profiling services to support clinical research and the development of oncology therapies in China.

Agenus Inc., a leader in developing novel immunological agents to treat various cancers, announced expanded data from the company’s phase 1b study of botensilimab in combination with balstilimab in patients with advanced sarcomas.

Immunocore Holdings plc announces that the three-year overall survival data from the KIMMTRAK Phase 3 trial in previously untreated HLA-A*02:01 positive patients with metastatic uveal melanoma has been published in The New England Journal of Medicine, and presented as a late breaking abstract in a mini oral session at the European Society for Medical Oncology Congress 2023.

Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 LITESPARK-005 trial investigating WELIREG, Merck’s first-in-class, oral hypoxia-inducible factor-2 alpha inhibitor, for the treatment of adult patients with advanced renal cell carcinoma that progressed following PD-1/L1 and vascular endothelial growth factor receptor targeted therapies.

ESSA Pharma Inc. announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide at the European Society of Medical Oncology 2023 Congress, taking place October 20-24, 2023, in Madrid, Spain.

Precede Biosciences announced the first clinical data from its proprietary liquid biopsy platform were presented in an oral presentation at the European Society for Medical Oncology Congress in Madrid, Spain, and simultaneously published in Nature Medicine.

Positive results from the primary analysis of the DUO-E Phase III trial showed that IMFINZI® plus platinum-based chemotherapy, followed by either IMFINZI monotherapy or IMFINZI plus LYNPARZA®, both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometrial cancer.

Eli Lilly and Company announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo® versus platinum-based chemotherapy.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced the updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer and other neuroendocrine tumor types in a poster at the European Society of Medical Oncology Congress 2023.

AnHeart Therapeutics, a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, announced positive interim results from its global pivotal Phase 2 clinical trial, TRUST-II.